In the unfolding legal landscape, Johnson & Johnson faces significant courtroom battles, with two mesothelioma trials currently taking place in Washington and Florida. These cases focus on allegations linking the company’s talc products to cancer, a legal issue that has persisted for years with thousands of similar lawsuits [details](http://www.law.com/2026/03/11/critical-mass-with-lawcoms-amanda-bronstad-two-talc-trials-take-off-against-johnson–johnson-abbott-faces-another-trial-over-preterm-infant-formula/){:target=”_blank”}. The outcomes of these trials may set critical precedents for the numerous pending cases.
Simultaneously, Abbott Laboratories is embroiled in a high-stakes trial concerning its formula products. The litigation involves four premature infants who developed necrotizing enterocolitis, a severe gastrointestinal condition, after consuming the company’s formula. This trial is part of a broader pattern of litigation over the health implications of formula products for premature infants, with previous cases drawing scrutinized attention to the manufacturer’s safety protocols and marketing practices.
In another legal development, attention is drawn to the appointment of leadership for lawsuits involving claims that Ozempic, a drug primarily used for diabetes and weight loss, as well as other similar medications, allegedly caused blindness in users. This case highlights a growing trend in pharmaceutical litigation, focusing on the adverse effects of well-known medications. Experts suggest that the appointment of experienced legal leadership may streamline the complex proceedings typically associated with pharmaceutical litigation.
These cases exemplify the intensive scrutiny and legal action facing major corporations over health and safety issues. The outcomes could influence not only financial consequences for the companies involved but also regulatory strategies and public health policies.